STUDY OF TECHNOLOGICAL PROPERTIES OF SUBSTANCE AND BASIC COMPOSITION FOR OBTAINING THE DRUG PRODUCT OF “BIOMAYRIN”

The low-molecular synthetic drugs, used for the treatment of tuberculosis nowadays, are highly toxic and do not have the ability to selectively penetrate into phagocytes; besides, they are quickly removed from the body without providing a prolonged action. To solve the existing problem, modern methods of modifying the properties of biologically active compounds by joint synthesis of antibiotic with high-molecular compounds, by incorporating antituberculosis drugs into the carrier polymers have been applied. These methods have made it possible to purposefully change their physical-chemical and medical-biological properties.

The aim of the work is to evaluate the technological properties of the substance of the combined anti-tuberculosis drug “Biomayrin” and to work out its drug product.

Materials and methods. The object of the study was the substance of the original medicinal preparation “Biomayrin”, obtained on the basis of high molecular compounds, and synthetic antituberculosis drugs by the molecular design method.

Results and discussion. The results of the comparative analysis of technological properties of the biomayrin substance and the prepared capsular masses with the addition of various antifriction agents are shown in the article. The introduction of antifriction agents greatly improved the technological properties of the substance. As a result, the angle of the natural slope decreased from 42.7° to 31–39°, and the fl owability increased to 2.6–3.6 g/s.

Conclusion. Thus, the infl uence of various antifriction agents on the technological properties of the substance of the anti-tuberculosis drug “Biomayrin” was investigated, which allowed to work out the optimal composition of the drug product.

anti-tuberculosis drugs, biomayrin, technological properties of the substance, antifriction substances, solid drug product

1. World Health Organization. WHO report 2016: Global tuberculosis report 2016 [Internet]. [cited 2017 Iul 11]. Available from: http://www.who.int/about/licensing/copyright_form/index. html.

2. Global report on surveillance and response «Multidrug and extensively drug resistant TB (M/XDRTB)» [Internet]. WHO, 2010. P. 1-71. [cited 2017 Iul 11]. Available from: http://apps.who.int/iris/bitstream/10665/44286/1/9789241599191_eng.pdf

3. Krasnoselskih IV, Shepochkina YuA, Garasko EV. Kapsulnaya forma – novyj podhod dlya lecheniya bolnyh tuberkulezom [Capsule form – a new approach for the treatment of patients with tuberculosis]. Pharmacy. 2012; 7:38. Russian.

4. Lebedeva NO, Sukhova EV. Formirovanie motivacii k lecheniyu u bolnyh tuberkulezom legkih [Formation of motivation to the treatment of patients with pulmonary tuberculosis]. Tuberculosis and Lung Diseases. 2006;12:13–6. Russian.

5. Registr lekarstvennyh sredstv. [Russian register of medicines]. [Internet]. 2017. 25-edition. [cited 2017 Iul 13]. Available from: http://www.rlsnet.ru. Russian.

6. Maghrabi J, Mojokina GN, Alyautdin RN, Oganesyan EA, Yelistratova NA. Razrabotka i farmakologicheskoe izuchenie nanosamalnyh form nekotoryh protivotuberkuleznyh preparatov [Development and pharmacological study of nanoparticle forms of some antituberculosis drugs]. Rossijskij medicinskij zhurnal. 2012;2:33–5. Russian.

7. Kaur K, Gupta A, Narang RK, Murthy RSR. Novel drug delivery systems: desired feat for tuberculosis. J. Adv. Pharm. Technol. Res. 2010;1(2):145–63.

8. Tsubota N, Tanimukai S. A clinical experience of rifampicin suppository for the treatment of pulmonary tuberculosis. Kekkaku. 2015. Jun; 90(6):543–7.

9. Shegokar Ranjita A, Shaal L, Mitri K. Present Status of Nanoplasticle Researche for Treatment of Tuberculosis. J. Pharm. Pharm. Sci. 2011;14(1):100–16.

10. Sabitha P, Ratna JV, Reddy KR. Design and evaluation of controlled release chitosan-calcium alginate microcapsules of antitubercular drugs for oral use. Int. J. Chem. Technol. Res. 2010;2(1):88–98.

11. Shomurotov ShA, Akhmedov OR, Turaev AS. Kombinirovannoe protivotuberkuleznoe sredstvo prolongirovannogo dejstviya [The combined antituberculosis drugs of prolonged action]. The patent application IAP 20160219 07.06.2016. Uzbekistan.

12. Shomurotov ShA, Ahmedov OR, Turaev AS. Kolichestvennoe opredelenie dejstvuyushchih veshchestv v protivotuberkuleznom preparate biomajrin [Quantitative determination of active ingredients in antituberculosis preparation biomayrin]. Farmacevticheskij vestnik Uzbekistana. Тashkent. 2013;1:45–9. Russian.

13. Gosudarstvennaya Farmakopeya Rossijskoj Federacii [State Pharmacopoeia of Russian Federation]. [Internet]. XIII edition. Moscow, 2015(Pt 2):215. [cited 2017 Iul 11]. Available from: http://www.femb.ru/feml. Russian.

14. Shomurotov ShA, Mamadullaev G, Turaev AS. Mediko-biologicheskie svojstva polisaharidnyh kompleksov izoniazida i etambutola [Medical and biological properties of polysaccharide complexes isoniazid and ethambutol]. Biomedicinskaya khimiya. Taskent. 2016; 62(1):45-9. DOI: 10.18097/PBMC20166201045. Russian.

15. Yemshanova SV, Sadchikova NP, Zuev AP. O kontrole razmera i formy chastic lekarstvennyh veshchestv [On the control the size and shape of particles of drugs]. Pharmaceutical Chemistry Journal. 2007;41(1):41 – 9. Russian.

16. Anil Kumar KN, Basu Ray S, Nagaraja V, Ashok MR. Encapsulation and release of rifampicin using poly (vinyl pyrrolidone) – poly (methacrylic acid) polyelectrolyte capsules. Materials Science and Engineering. 2009;29(8):2508–13. DOI:10.1016/j.msec.2009.07.019

17. Panchagnula R, Agrawal S, Ashokraj Y, Varma M, Sateesh K, Bhardwaj V, Bedi S, Gulati I, Parmar J, Kaul CL, Blomberg B, Fourie B, Roscigno G, Wire R, Laing R, Evans P, Moore T. Fixed – dose comdinations for tuderculosis: Lessons learned from a clinical, formulation and regulatory perspective. Methods Find Exp Clin Pharmacol. 2004;26(9):703–21. DOI: 10.1358/mf.2004.26.9.872568

18. Yemshanova SV, Abramovich RA, Potanina OG. Vliyanie formy i razmera chastic substancij na kachestvo gotovyh lekarstvennyh sredstv [Effect of the shape and size of the particles of substances on the quality of fi nished medicaments]. Research & Production Journal. 2014;2(7):50–63. Russian.

19. Farmacevticheskaya tekhnologiya. Tverdye lekarstvennye formy Uchebnoe posobie [Pharmaceutical of technology. Solid dosage forms. Tutorial]. Professor Kedik SA, editor. Moscow, 2011. 661 p. Russian.

20. Shablakova AS, Petrov AYu, Ulomskiy EN. Znachimye tekhnologicheskie svojstva substancii lekarstvennogo veshchestva [Signifi cant technological properties of the drug substance]. Journal of Ural Medical Academic Science. 2011;3/1(35):91. Russian.